A technology platform that allows cost-effective DNA testing for early diagnosis and treatment of infectious diseases.
Incubated Since 2015 Headquarters Bangalore, India Sector Healthcare Sub-sector Biotechnology, diagnostics
Portfolio Manager Nirupa Rao
"Taking these laboratory based tests and making them ‘field-friendly’, if successful, could start to make a difference for the millions who suffer from an infection: from malaria to AIDS.”
- Sudeshna Adak, Omix labs.
Sudeshna Adak holds both a Bachelor and a Master of Statistics degree in statistics from Indian Statistical Institute and a Ph.D in statistics from Stanford University. She has in the past worked for multiple research institutes such as IBM India research Lab and Harvard School of Public Health, GE Global Research and GE Healthcare.
Abhinanda Sarkar holds both a Bachelor and a Master of Statistics degree in mathematical statistics and probability from Indian Statistical Institute and a Ph.D in statistics from Stanford University. He was a lecturer at MIT and e worked for organisations such as IBM and GE Global Research before starting OmiX Labs.
Infectious diseases constitute nearly 50% of the disease burden in India and much higher than 50% in people at the base of the pyramid and in children below the age of 5. Delay in diagnosis and late or inappropriate treatment increases the risk of complications, higher morbidity and mortality and increased cost to the patient.
The nearest primary health centre for someone who is sick is likely to be 5 km away, and the medical officer there is unlikely to be familiar with the wide range of infectious diseases that are prevalent in the region and probably will not have access to a microbiology laboratory
OmiX Labs is developing a novel technology platform that allows for DNA testing for pathogens, outside of laboratory settings. Analogous to the glucose strips and glucometer devices for glucose testing at home, the OmiX platform detects pathogen DNA present in a few drops of blood on a novel disposable biochip, with a proprietary enrichment and assay on the chip and a reader for DNA analysis.
The platform is designed to bring advances in molecular diagnosis and create access where there is none: mostly in lower income groups who do not have access to laboratories and yet need early and accurate detection to have a better chance for cure.